Subtype
Gastroesophageal Junction Adenocarcinoma
CI-CAN-00005403Explore in graph →
228 active trials9 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005403Explore in graph →
Clinical trials
695 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (82)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07102901 | Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 351 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07018661 | [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer(PLASTIC-3) | recruiting | Phase 2 / Phase 3 | 250 | Leiden University Medical CenterOTHER | 1 | Aug 27, 2025 |
| clinicaltrials |
| NCT06329973 | Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer | recruiting | Phase 1 / Phase 2 | 70 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 17, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT06028737 | Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer(OCTASUR) | recruiting | Phase 2 / Phase 3 | 150 | Ukrainian Society of Clinical OncologyOTHER | 2 | May 6, 2025 | clinicaltrials |
| NCT06422403 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers(VALUE-CHECK) | recruiting | Phase 2 | 360 | National University Hospital, SingaporeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06572319 | Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens | recruiting | Phase 1 / Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06560528 | Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression | recruiting | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT05177133 | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)(AuspiCiOus) | recruiting | Phase 2 | 25 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06196697 | AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer | recruiting | Phase 2 | 50 | Harbin Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06221748 | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | recruiting | Phase 2 / Phase 3 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT04660760 | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 116 | Academic and Community Cancer Research UnitedOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06155383 | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | recruiting | Phase 2 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT06121700 | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer(Miracle-G) | recruiting | Phase 2 | 55 | Fudan UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT04018872 | Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer | recruiting | Phase 2 | 78 | Dallas VA Medical CenterFED | 1 | Nov 4, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 10, 2025source: clinicaltrials